Spain

Different Doses of BI-1607 in Combination With Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors – NCT04336241

This Phase 1 clinical trial is investigating a new type of immunotherapy called RP2 for people with advanced solid tumours, including metastatic uveal melanoma. RP2 is an engineered herpes simplex virus (HSV-1) designed to infect and destroy cancer cells while also stimulating the body’s immune system to recognise and attack the tumour. The treatment has […]

Different Doses of BI-1607 in Combination With Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors – NCT04336241 Read More »

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301)

This Phase 3 clinical trial, known as PRISM-MEL-301, is investigating whether a new immunotherapy treatment called brenetafusp (IMC-F106C), given in combination with nivolumab, works better than standard nivolumab-based treatment for people with advanced melanoma that cannot be removed surgically or has spread to other parts of the body. The study is specifically for patients who

IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (PRISM-MEL-301) Read More »

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors – NCT04262466

This early-phase clinical trial is testing a new treatment called brenetafusp (IMC-F106C) for adults with advanced cancers that test positive for a specific protein called PRAME. Brenetafusp is a type of immunotherapy known as an ImmTAC®, which is designed to help the immune system find and destroy cancer cells. To take part in the trial, patients must also

Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors – NCT04262466 Read More »

Different Doses of BI-1607 in Combination with Pembrolizumab and Ipilimumab, in Participants with Unresectable or Metastatic Melanoma – NCT06784648

This is an early-phase clinical trial testing a new drug called BI-1607 for people with melanoma that has spread or cannot be removed by surgery. The aim is to see whether combining BI-1607 with two existing treatments, ipilimumab and pembrolizumab, is safe and more effective than current options. BI-1607 is designed to help the body’s

Different Doses of BI-1607 in Combination with Pembrolizumab and Ipilimumab, in Participants with Unresectable or Metastatic Melanoma – NCT06784648 Read More »

The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy – NCT04573881

This is a single-arm, non-randomized prospective trial designed to assess the effectiveness and safety of the HistoSonics System, a novel treatment for primary or metastatic liver tumors. The trial aims to evaluate how well the system works and its safety profile in targeting liver tumors.

The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy – NCT04573881 Read More »

Study of Roginolisib in UM Patients (OCULE-01) – NCT06717126

This Phase II study is being conducted at multiple centres to evaluate the effectiveness of a drug called Roginolisib in treating advanced or metastatic ocular/uveal melanoma. The study is open-label, meaning all participants will know they are receiving the treatment, and participants will be randomly assigned to different treatment groups to assess the anti-tumour activity

Study of Roginolisib in UM Patients (OCULE-01) – NCT06717126 Read More »

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma – NCT05987332

This Phase 1/2 multi-centre, open-label basket study aims to assess the safety and effectiveness of IDE196 in treating solid tumours with specific genetic changes, such as GNAQ or GNA11 mutations or PRKC fusions. The study includes patients with metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other types of solid tumours.

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma – NCT05987332 Read More »